Click Sign-Up Today to register an account to access your prescriptions. Please note: Your previous login credentials will not work with this new service. Download our NEW Mobile App! See details below!
1224 Gay St, Dandridge, TN 37725 Phone: (865) 397-3444 | Fax: (865) 397-6279 Mon-Fri 8:00am - 6:00pm | Sat 9:00am - 2:00pm | Sun Closed
Tinsley Bible Drug Co. Logo

Manténgase sano!

A Common Trait Between Newborns And Alzheimer’s Patients?
  • Posted August 21, 2025

A Common Trait Between Newborns And Alzheimer’s Patients?

The brains of newborns have a surprising trait in common with adults who’ve developed Alzheimer’s disease, a recent study says.

Both have elevated blood levels of a well-known biomarker for Alzheimer’s – a protein called phosphorylated tau, researchers reported recently in the journal Brain Communications.

Tau is associated with the amyloid beta plaques and tau tangles that riddle the brains of people with Alzheimer’s, researchers noted.

But in newborns, this tau surge appears to support healthy brain development, helping neurons grow and form connections with other neurons, researchers found.

This hints that human brains might have built-in protection against tau’s potentially damaging effects, so newborns can tolerate and even benefit from heavy levels of tau without triggering Alzheimer’s-like damage, researchers said.

“We believe that understanding how this natural protection works — and why we lose it as we age — could offer a roadmap for new treatments,” lead investigator Fernando Gonzalez-Ortiz, a doctoral student at the University of Gothenburg in Sweden, said in a news release.

“If we can learn how the newborn brain keeps tau in check, we might one day mimic those processes to slow or stop Alzheimer’s in its tracks,” he added.

For the new study, researchers compared blood levels of a type of tau called p-tau217 in more than 400 people, including newborns, teenagers, young adults, seniors and people with either mild cognitive impairment or Alzheimer’s.

Blood testing for p-tau217 recently received FDA approval for use in diagnosing Alzheimer’s disease, researchers noted.

Results showed that newborns had the highest levels of p-tau217 — even higher than those found in diagnosed Alzheimer’s patients, researchers said.

The levels were particularly elevated in premature babies, and started to decrease over the first few months of life until they settled to levels typically found in young adults.

Researchers also found that p-tau217 levels were closely linked to how early babies were born. The earlier the birth, the higher the baby’s tau levels, suggesting that it serves a role supporting rapid brain growth under challenging developmental conditions.

Future studies should explore the protective mechanisms that protect babies’ brains from the development of tau tangles found in Alzheimer’s patients, researchers said.

More information

The Alzheimer’s Association has more on amyloid beta and tau.

SOURCE: University of Gothenburg, news release, June 24, 2025

HealthDay
El servicio de noticias de salud es un servicio para los usuarios de la página web de Tinsley Bible Drug Co. gracias a HealthDay. Tinsley Bible Drug Co. ni sus empleados, agentes, o contratistas, revisan, controlan, o toman responsabilidad por el contenido de los artículos. Por favor busque consejo médico directamente de un farmacéutico o de su médico principal.
Derechos de autor © 2025 HealthDay Reservados todos los derechos.

Compartir

Etiquetas